资讯

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...
The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...
2025年5月份,美国食品药品监督管理局(FDA)正式批准了一款由日本生物技术公司 Fujirebio Diagnostics ...
美国食品药品监督管理局(FDA)周五表示,该机构已批准Fujirebio ...
Investing.com — 美国食品药品监督管理局 (FDA)已授权首个基于血液的诊断工具,用于帮助检测出现认知能力下降迹象和症状的成年人的阿尔茨海默病。Lumipulse G pTau217/ß-Amyloid ...
The Food and Drug Administration cleared a new kind of test for Alzheimer’s disease designed to be more accessible and less ...
The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio enables early detection of amyloid plaques through a non-invasive blood ...
Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...
The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.
The FDA has cleared the first-ever blood test for early Alzheimer's detection, which the agency says reduces the need for ...
FDA approves Lumipulse G, the first blood test that can help in the diagnosis of Alzheimer's disease. Read more here.
The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...